《大行報告》里昂:過去Jehoshaphat發表沽空報告成功率低 創科(00669.HK)及時恢復交易視為正面
里昂發表研究報告指,沽空機構Jehoshaphat Research (JR)在過去發表的9份沽空報告中,僅一、兩次錄得成功,其中有六次更在其發表報告後錄得反彈,或為沽空人士帶來負回報。
該行提到,由於分散式阻斷服務攻擊(DDOS),JR的網頁一度無法瀏覽。該行相信,一旦創科(00669.HK)詳細闡述了做空報告,或會看到創科與JR之間的另一輪回應,又認為該股票迅速恢復交易是正面信號,重申「買入」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.